MedPath

Comparative Single-dose Bioavailability Clinical Study of Different Coenzyme Q10 Products

Not Applicable
Completed
Conditions
Coenzyme Q Deficiency
Registration Number
NCT05272228
Lead Sponsor
University of Primorska
Brief Summary

The randomized, open-label, three period crossover single-dose bioavailability study with three coenzyme Q10 products

Detailed Description

The randomized, open-label, three period crossover single-dose bioavailability study with three coenzyme Q10 products will include 25 subjects who will test three different coenzyme Q10 products. Serum concentration of coenzyme Q10 will be measured.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
25
Inclusion Criteria
  • subject informed consent form
  • aged between 40 and 55 years old
  • body mass for women 65± 5 kg and for men 85± 5 kg
  • non-smoking
  • healthy, without cardio-vascular diseases, diabetes, neurodegenerative diseases
  • absence of any prescribed medication during the study
  • willing to avoid a consumption of any food supplements at least 2 weeks before and during the study
  • willing to study all study procedures
Exclusion Criteria
  • cardio-vascular diseases,
  • diabetes,
  • neurodegenerative diseases,
  • gastrointestinal disorders
  • hypotension
  • pregnancy
  • breast-feeding
  • intake of any prescribed medication within two week of the beginning of the study
  • intake of any food supplements within two week of the beginning of the study
  • drug or alcohol abuse

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Primary Outcome Measures
NameTimeMethod
Serum coenzyme Q10 concentrations0,2,4,6,8,12 and 24 hours after ingestion

Serum coenzyme Q10 concentrations will me measured in all three different coenzyme Q10 products with ELISA kit for coenzyme Q10

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

University of Primorska

🇸🇮

Izola, Slovenia

University of Primorska
🇸🇮Izola, Slovenia

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.